Goodyear, C., Patel, A., Barnes, E., Willicombe, M., Siebert, S., de Silva, T., Snowden, J., Lim, S., Bowden, S., Billingham, L., Richter, A., Carroll, M., Carr, E., Beale, R., Rea, D., Parry, H., Pirrie, S., Lim, Z., Satsangi, J., Dunachie, S., Cook, G., Miller, P., Basu, N., Gilmour, A., Hodgkins, A., Evans, L., Hughes, A., Longet, S., Meacham, G., Yong, K., A'Hearne, M., Koh, M., Burns, S., Orchard, K., Paterson, C., McIlroy, G., Murray, S., Thomson, T., Dimitriadis, S., Goulston, L., Miller, S., Keillor, V., Prendecki, M., Thomas, D., Kirkham, A., McInnes, I. & Kearns, P. 2024, 'Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial', The Lancet Rheumatology, 6(6), pp. E339-E351. http://dx.doi.org/10.1016/S2665-9913(24)00065-1